News
7d
Zacks.com on MSNHere's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
15d
Zacks Investment Research on MSNHow Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...
The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, Tukysa and Tivdak — to the company’s portfolio. In first-quarter 2025, oncology contributed more than 25% to Pfizer’s ...
Pfizer said it still expects adjusted 2025 profit of $2.80 a share to $3 a share, while analysts expect full-year earnings of $2.94 a share.
The goal is to make drug prices more in line with European ones. If this were the case, it could result in a massive 24% hit on all firms’ US drug revenue, detrimental to Pfizer.
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...
Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...
Pfizer appears to be a very promising stock to buy if you're looking for income. That 7.3% dividend yield is terrific, and even if it gets slashed, it will likely still be substantial.
6d
Zacks Investment Research on MSNHow Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results